Trial Profile

A Prospective, Non-interventional, Registry Study of Patients Initiating Pharmacologic Therapy for Overactive Bladder in Taiwan, Korea and China

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darifenacin (Primary) ; Fesoterodine (Primary) ; Imidafenacin (Primary) ; Mirabegron (Primary) ; Oxybutynin (Primary) ; Propiverine (Primary) ; Solifenacin (Primary) ; Tolterodine (Primary) ; Trospium chloride (Primary)
Indications Overactive bladder
Focus Therapeutic Use
Sponsors Astellas Pharma

Most Recent Events

17 Oct 2021 Results presented at the 51st Annual Meeting of the International Continence Society
21 Apr 2020 Status changed from active, no longer recruiting to completed.
17 Oct 2019 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com